RT Journal Article
SR Electronic
T1 Early introduction and rise of the Omicron SARS-CoV-2 variant in highly vaccinated university populations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.27.22269787
DO 10.1101/2022.01.27.22269787
A1 Petros, Brittany A.
A1 Turcinovic, Jacquelyn
A1 Welch, Nicole L.
A1 White, Laura F.
A1 Kolaczyk, Eric D.
A1 Bauer, Matthew R.
A1 Cleary, Michael
A1 Dobbins, Sabrina T.
A1 Doucette-Stamm, Lynn
A1 Gore, Mitch
A1 Nair, Parvathy
A1 Nguyen, Tien G.
A1 Rose, Scott
A1 Taylor, Bradford P.
A1 Tsang, Daniel
A1 Wendlandt, Erik
A1 Hope, Michele
A1 Platt, Judy T.
A1 Jacobson, Karen R.
A1 Bouton, Tara
A1 Yune, Seyho
A1 Auclair, Jared R.
A1 Landaverde, Lena
A1 Klapperich, Catherine M.
A1 Hamer, Davidson H.
A1 Hanage, William P.
A1 MacInnis, Bronwyn L.
A1 Sabeti, Pardis C.
A1 Connor, John H.
A1 Springer, Michael
YR 2022
UL http://medrxiv.org/content/early/2022/01/28/2022.01.27.22269787.abstract
AB The Omicron variant of SARS-CoV-2 is transmissible in vaccinated and unvaccinated populations. Here, we describe the rapid dominance of Omicron following its introduction to three Massachusetts universities with asymptomatic surveillance programs. We find that Omicron was established and reached fixation earlier on these campuses than in Massachusetts or New England as a whole, rapidly outcompeting Delta despite its association with lower viral loads. These findings highlight the transmissibility of Omicron and its propensity to fixate in small populations, as well as the ability of robust asymptomatic surveillance programs to offer early insights into the dynamics of pathogen arrival and spread.Competing Interest StatementM.S. is co-founder of, shareholder in, and advisor to Rhinostics Inc. M.G, D.T., S.R., and E.W. are employed by Integrated DNA Technologies. C.M.K. is co-founder of Biosens8, Inc. J.H.C. is a consultant for Cell Signaling Technologies. W.P.H. serves on Scientific Advisory Boards for Biobot Analytics Inc. and Merck. P.C.S. is a founder of and shareholder in Sherlock Biosciences, and is both on the Board and serves as shareholder in the Danaher Corporation. Funding StatementB.A.P. is supported by the National Institute of General Medical Sciences (grant T32GM007753). L.F.W. is supported by the National Institute of General Medical Sciences (grant R35GM141821). J.H.C. acknowledges funding from Boston University for SARS-CoV-2 surveillance, from the Massachusetts Consortium on Pathogen Readiness (MassCPR), and from the China Evergrande Group. W.P.H., T.P.B., and K.R.J. also acknowledge support from MassCPR. T.B. is supported by the National Institute of Health (NIAID K23 grant AI152930-01A1). B.L.M. is supported by the Centers for Disease Control and Prevention SARS-CoV-2 Baseline Genomic Surveillance contract (75D30121C10501 to Broad Institute via the Clinical Research Sequencing Platform, LLC), a CDC Broad Agency Announcement (75D30120C09605 to B.L.M), and the Rockefeller Foundation (2021 HTH 013 to B.L.M. and P.C.S.). M.S. is supported by the National Institute of Health (grant 5R01GM120122). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Harvard Longwood Campus IRB (protocol #20-1877) gave ethical approval for work with Harvard University samples. These samples were covered by an exempt determination (EX-7295) at the Broad Institute of MIT and Harvard. Boston University IRB (protocol #6122E) gave ethical approval for work with Boston University samples. Northeastern University IRB (protocol #21-02-07) provided an exempt determination for Northeastern University samples, whose metadata was shared with the authors under Data Use Agreement 20-1481.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCustom R scripts are available at https://github.com/bpetros95/omi-uni. De-identified input data is available upon request. https://github.com/bpetros95/omi-uni